Questions discussed in this category
What is your evaluation approach for RAI response? What cumulative dose do you use in practice for deciding a patient is RAI refractory?
The phase 2 trial of pembrolizumab in JCO 2019 showed efficacy, and I have patients preferring to avoid chemotherapy.
20284102026808
Papers discussed in this category
J Endocr Soc, 2019 Oct 11
J Clin Oncol, 2020 Jan 1
Am J Transplant, 2016 Jun 09
Transplantation, 2021 Apr 27
Surgery, 2017 Jun 16